Overview

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Status:
Recruiting
Trial end date:
2023-03-10
Target enrollment:
Participant gender:
Summary
A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009 monotherapy in both Hormone Receptor(HR) positive/HER2 negative breast cancer and in TNBC, and evaluate CX-2009+CX-072 in TNBC
Phase:
Phase 2
Details
Lead Sponsor:
CytomX Therapeutics